PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Elbrus Capital Funds invest RUB750m in BREFFI

Elbrus Capital Fund III has acquired a sizeable minority stake in BREFFI, a Russian omnichannel pharma marketing company. The transaction amount was RUB750 million. Most of the funds will be applied by the company towards scaling up its operations and creating new digital products for the healthcare and pharma sectors.

Since its inception, the main focus of BREFFI has been promotion of branded pharma products in Russia, primarily through the medical community. Currently BREFFI has over 100 clients, most of which are international pharmaceutical companies operating in Russia. BREFFI’s revenue in 2021 is to exceed RUB500 million.
 
This is the first time that BREFFI has raised capital from an outside investor. Funding received from Elbrus Capital Funds will be used for further development of the business. The company plans to scale up its successful services, expand into promising adjacent areas and enhance its IT products development. The company’s valuation has not been disclosed. 

BREFFI’s founders, Evgeniy Gordeev, Irina Shramova, and Anton Bondarenko, will continue managing the business, retaining control over key decisions.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured